Posted by Michael Wonder on 27 May 2021
FDA approves Biohaven's Nurtec ODT (rimegepant) for prevention: now the first and only migraine medication for both acute and preventive treatment
27 May 2021 - Nurtec ODT 75 mg is the first oral CGRP antagonist approved to prevent migraine.
Biohaven Pharmaceutical today announced that the U.S. FDA has approved Nurtec ODT (rimegepant 75 mg) for the preventive treatment of migraine.
